Results 101 to 110 of about 12,486 (248)

Prediction of Monoclonal Antibody Pharmacokinetics in Pediatric Populations Using PBPK Modeling and Simulation

Pharmaceutics
Background: Accurately determining pediatric dosing is essential prior to initiating clinical trials or administering medications in routine clinical settings. In children, ethical considerations demand careful evaluation of both safety and effectiveness.
Chiara Zunino, Virginie Gualano, Haiying Zhou, Viera Lukacova, Maxime Le Merdy   +4 more
doaj   +1 more source

Modeling Three-dimensional Invasive Solid Tumor Growth in Heterogeneous Microenvironment under Chemotherapy

, 2018
A systematic understanding of the evolution and growth dynamics of invasive solid tumors in response to different chemotherapy strategies is crucial for the development of individually optimized oncotherapy.
Chen, Guo, Fan, Qihui, Hai, Miaomiao, Hu, Zhijian, Jiao, Yang, Liu, Liyu, Liu, Ruchuan, Shuai, Jianwei, Xie, Hang, Yang, Jiaen, Yang, Yue   +10 more
core   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +1 more source

Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 457-469, February 2026.
Physiologically Motivated Sequential Population Modeling of Albumin Trends and Vedolizumab Pharmacokinetics for Pregnancy Dosing Regimen Optimization. The pharmacokinetics (PK) of monoclonal antibodies (mAbs) during pregnancy remains poorly characterized, despite active inflammatory bowel diseases (IBD) being the greatest risk factor for adverse ...
Zrinka Duvnjak, Robin Michelet, Casper Steenholdt, Ella S.K. Widigson, Cæcilie Skejø, João A. Abrantes, Wilhelm Huisinga, Mette Julsgaard, Charlotte Kloft   +8 more
wiley   +1 more source

Development of a Pregnancy‐Specific Physiologically Based Pharmacokinetics (PBPK) Model for Aspirin

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Aspirin is one of the most commonly used medications in pregnancy, particularly for the prevention of hypertensive disorders. Despite aspirin's widespread use in pregnancy for preeclampsia prevention, its pharmacokinetics (PK) across all trimesters remain poorly characterized, complicating optimal dosing recommendations. To develop a pregnancy‐
Ana Collins‐Smith, Ananth Kumar Kammala, Mitch A. Phelps, Xiao Ming Wang, Ramkumar Menon, Maged M. Costantine   +5 more
wiley   +1 more source

Evaluation of the PK/PD Changes on MASLD‐Related Population—An Example From Simultaneous Acetaminophen Parent‐Metabolite PBPK/PD Modeling

CPT: Pharmacometrics & Systems Pharmacology
Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) may exhibit altered pharmacokinetics (PK) and pharmacodynamics (PD) of drugs compared with healthy populations.
Shanshan Zhao, Lan Zhang
doaj   +1 more source

A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans

ADMET and DMPK, 2019
Oseltamivir phosphate (OP, Tamiflu®) is a widely used prodrug for the treatment of influenza viral infections. Orally administered OP is rapidly hydrolyzed by the carboxylesterases in animals to oseltamivir carboxylate (OC), a potent influenza virus ...
Guanghua Gao, Francis Law, Ricky Ngok Shun Wong, Nai Ki Mak, Mildred Sze Ming Yang   +4 more
doaj   +1 more source

Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. [PDF]

, 2018
Pharmacokinetic/pharmacodynamic (PKPD) modeling is important in the design and conduct of clinical pharmacology research in children. During drug development, PKPD modeling and simulation should underpin rational trial design and facilitate extrapolation
A Cram, A Hooker, A Rao, AA Vinks, AH Thomson, AK Done, AM Johansson, AN Edginton, AN Edginton, AR Maharaj, AR Maharaj, B Green, B Quijano Ruiz, BJ Anderson, BJ Anderson, C Stockmann, CA Knibbe, CC Peck, CF Weiss, Charlotte I. S. Barker, CI Barker, CIS Barker, D Lin, DB Hawcutt, DJ Eleveld, E Germovsek, E Germovsek, E Germovsek, E Kimland, E Manolis, E Manolis, EI Ette, EI Ette, Eva Germovsek, F Rodieux, FG Benedict, G Langdon, G Nellis, GEP Box, GJ Robbie, GL Kearns, H Kimko, H Mulla, H Padari, H Shirkey, HG Eichler, HM Jones, HS Al-Sallami, I Adatia, I Bains, I Mahmood, I Mahmood, I Mahmood, IH Bartelink, J Alcorn, J Dunne, J Gillis, J Lerman, J Nyberg, J Nyberg, JA Roberts, JD Crawford, JE Sager, JF Standing, JF Standing, JF Standing, JK Roberts, JM Nicolas, Joseph F. Standing, JR Bellis, JS Barrett, JS Barrett, JS Barrett, JT Gilman, K Kipper, KD Wittmeier, KL Brouwer, L Aarons, L Cuzzolin, L Harnisch, L Harnisch, LE Kelly, LV Hampson, M Cella, M Cella, M Cella, M Danhof, M Jamei, M Kleiber, M Kleiber, M Minocha, M Neely, M Pfister, M Rowland, MA Montenegro, MA Turner, MA Turner, MA Turner, MA Turner, Mike Sharland, ML Christensen, MM Rhodin, MO Karlsson, MY Peeters, N Holford, N Kleiber, N Modi, NH Holford, P Espie, PA Valitalo, PD Joseph, PH Graaf van der, RE Kauffman, RF Cock De, RM Ward, RM Ward, RS Kadam, RW Jelliffe, S Conroy, S Duffull, S Feng, S Hennig, S Hennig, S Kanoh, S Leroux, SC McLeay, SE Tett, SG Wicha, SM MacLeod, SW Briggs, T Schechter, TA Leil, TA Leil, TH Nguyen, TN Johnson, TN Johnson, TN Johnson, TP Klassen, TS Samant, V Ramos-Martin, VH Tam, W Knebel, W Van’t Hoff, W Zhao, WA Silverman, Y Wang   +145 more
core   +2 more sources

Managing Drug–Drug Interactions Involving the Non‐Prescription Opioid Loperamide Through Physiologically Based Pharmacokinetic Modeling

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Loperamide is a widely used nonprescription peripherally acting opioid indicated for diarrhea. Loperamide undergoes extensive first‐pass metabolism, primarily by cytochrome (CYP) 3A and CYP2C8, with minor contributions from CYP2B6 and CYP2D6, and intestinal efflux by P‐glycoprotein (P‐gp).
Zhu Zhou, Garrett R. Ainslie, Mengyao Li, Jean Dinh, Maciej J. Zamek‐Gliszczynski, Ping Zhao, Mary F. Paine   +6 more
wiley   +1 more source